PRESIDENT’S UPDATE January 2021
With the merger of Mylan and Upjohn finally completed it didn’t take long for changes to be announced. The new company, known as Viatris (NASDAQ: VTRS) has announced that they will be closing Mylan’s first manufacturing plant located in Morgantown, WV. The plant, expected to close in July, employs over 1,600 people. Additionally, up to 15 other plants are expected to close throughout the world reducing their workforce by up to 20% or 9,000 people. Mylan’s CEO Heather Bresch who was involved in putting the merger together, recently stepped down from her position at Mylan. Her father coincidentally is former West Virginia Governor and current U.S. Senator Joe Manchin.
Teva recently received the first approval to market two strengths of generic Tirosint. This triggered a deal that Lannett had with brand manufacturer IBSA to launch all 12 strengths of their brand under the Lannett label. We have all strengths of the Authorized Generic (AG) in stock.
Hikma just received approval for their generic version of Advair Diskus. Prasco has been marketing the AG for almost two years through a deal with GSK. While Hikma’s product may be in short supply for a little while we expect to see market prices decline slightly.
Generic Chantix could be available at any time. Four companies are expected to receive approval and an AG is also possible. Brand sales in the U.S. were almost a billion dollars last year. Still no word as to when generic Restasis will be available but there are a few companies expecting it any day. Six manufacturers are expected to launch the first generic Northera caps at the end of February. Check with your Auburn Account Manager for information on these and more.
Make sure that you keep checking GenericBid.com for the latest great deals on our weekly auctions. It’s a fun and easy way to save a lot of money!